A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

Study Summary

This is a Phase 3, global, randomized, open-label, multicenter, trial evaluating brelovitug (BJT-778) vs bulevirtide for the treatment of chronic hepatitis delta infection (CHD). The main goal of this study is to test the effectiveness of brelovitug compared to bulevirtide as a long-term treatment in patients with chronic HDV infection.

Conditions

Chronic Hepatitis D Infection

Interventions / Drugs

Brelovitug 300 mg Bulevirtide 2 mg and Brelovitug - 300 mg

View on ClinicalTrials.gov ↗

Sponsor

MIRM

Mirum Pharmaceuticals

Liver Disease

D37/100

Study Details

Enrollment172 participants

Primary Completion—

Lead SponsorMirum Pharmaceuticals, Inc.

Data Retrieved2026-04-11 04:21:18.704709+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.